|
TOP NEWS
Regeneron Ducks Amgen's Eylea Antitrust Counterclaims
By Bryan Koenig
A West Virginia federal judge dismissed key counterclaims and defenses Tuesday that Amgen had raised against Regeneron's patent infringement lawsuit targeting bids by multiple would-be rivals to produce biosimilar versions of eye medication Eylea, preserving only arguments that Regeneron waited too long to pursue the patent.
Opinion attached |
Read full article »
| Save to favorites »
LITIGATION
POLICY & REGULATION
ENFORCEMENT
EXPERT ANALYSIS
LEGAL INDUSTRY
|